Last reviewed · How we verify
DTcP
DTcP is a recombinant protein subunit vaccine that stimulates immune responses against diphtheria, tetanus, and pertussis antigens.
DTcP is a recombinant protein subunit vaccine that stimulates immune responses against diphtheria, tetanus, and pertussis antigens. Used for Prevention of diphtheria, tetanus, and pertussis in pediatric and adult populations.
At a glance
| Generic name | DTcP |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
DTcP combines diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens to induce protective humoral and cellular immunity. The vaccine is designed to prevent infection by these three bacterial pathogens through activation of B and T cell responses against their respective virulence factors.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in pediatric and adult populations
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (PHASE1)
- Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine (PHASE3)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (PHASE3)
- Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTcP CI brief — competitive landscape report
- DTcP updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI